Previous 10 | Next 10 |
Agile Therapeutics, Inc. (AGRX) Q2 2020 Earnings Conference Call August 11, 2020 16:30 ET Company Participants Matthew Riley - Investor Relations Alfred Altomari - Chairman, President & Chief Executive Officer Dennis Reilly - Senior Vice President & Chief Financial Office...
Are These Top Penny Stocks To Buy Just Because They’re Low-Priced? I don’t think penny stocks will ever get old. Tuesday’s trading session alone saw some of the wildest and most profitable trading of the week so far. There were also plenty of penny stocks that reached ...
Agile Therapeutics (NASDAQ: AGRX ) : Q2 GAAP EPS of -$0.12 beats by $0.02 . Cash and Cash Equivalents of $87.2M. Shares +1.9% . Press Release More news on: Agile Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, ,
PRINCETON, N.J., Aug. 11, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that Al Altomari, Chairman and Chief Executive Officer, will participate in a panel discussion as part of Maxim Group’s M-Vest Virtual Conference ...
Twirla ® on Track for Commercial Launch in Fourth Quarter 2020 $87.2 Million in Cash and Cash Equivalents as of June 30, 2020 Management to Host Conference Call at 4:30 PM ET PRINCETON, N.J., Aug. 11, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a wo...
Live Conference Call and Webcast at 4:30 p.m. ET PRINCETON, N.J., July 21, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a forward-thinking women’s healthcare company, today announced it will report second quarter 2020 financial results after the market close...
BioMarin Offers Additional Data for Valoctocogene Roxaparvovec Gene Therapy BioMarin Pharmaceutical Inc. ( BMRN ) provided an addendum to its previously announced four year update of an investigational gene therapy for treating severe hemophilia A. The study involved six patients who wer...
PRINCETON, N.J., June 16, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced that the Company will be added to the Russell 3000® and 2000® Indexes, effective after the U.S. market opens on June 29, 2020, as part...
Agile Therapeutics, Inc. (AGRX) Q1 2020 Earnings Conference Call May 05, 2020, 16:30 ET Company Participants Matthew Riley - IR Alfred Altomari - Chairman, President & CEO Dennis Reilly - SVP & CFO Conference Call Participants Daniel Busby - RBC Capital Markets Ti...
PRINCETON, N.J., May 11, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced that Al Altomari, Chairman and Chief Executive Officer, will participate in a virtual fireside chat as part of the 2020 RBC Capital Markets Global ...
News, Short Squeeze, Breakout and More Instantly...
Agile Therapeutics Inc. Company Name:
AGRX Stock Symbol:
OTCMKTS Market:
Agile Therapeutics Inc. Website:
First Quarter Net Revenue Increased 58% and Factory Sales Increased 3% from Fourth Quarter 2023 Twirla First Quarter 2024 Demand Rebounded 18% from Fourth Quarter 2023 PRINCETON, N.J., May 15, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Pink: AGRX), a women's healthcare com...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...
Full Year 2023 Net Revenue Increased 80% from 2022 While OPEX Decreased 33% Twirla Demand and Factory Sales Up 121% and 114% Respectively in 2023 vs 2022 Company Completes Pay-Off of Debt Facility in First Quarter 2024 Twirla Demand Expected to Rebound in First Quarter 2...